Phase 2 in Israel. Partnered with MGH and Mayo clinic in the US (two of the best research institutions in the world) to start a phase 2 trial here in the 3rd quarter. Compassionate use on a rabbi in Israel worked well (...he is still alive). Company recently got a new CEO whose compensation is basically based on getting the company uplisted. a 10:1 or 20:1 reverse split was approved at the shareholder meeting in April. Most likely this thing pops up to above .25 cents and they reverse split it to gain eligibility for Nasdaq. The have orphan drug status from the FDA because ALS is a rare disease, so they would have a few years of protected profits, and just about any treatment would be better than the current BS which extends life by about 6 months and costs thousands of dollars per year. Other than that, the share price bounces between about .20 and .25 cents.
Speculations: They are probably looking at about a year or two of trials in the US, depending on how well it works. I would say phase two finishes in the 2nd 3rd quarter of 2014, results published during the 4th quarter. They have no problem getting funding from Israel, and working with MGH/Mayo should lead to plenty of other funding avenues. Following a successful phase 2 and securing the necessary funding, Phase 3 sometime late in 2014 or early 2015, finishing up probably 12 months after that.
Basically, it is not a great stock to flip. The price really hasn't moved much below .20 or much above .25. there were a couple hits down to about 17, and a couple up to around 30, but the price is pretty damn stable for a penny stock. Should be a decent company to hold. A reverse split here would not be a sign of desperation, but would be a way to get institutional investors on board which requires a share price of over a couple bucks. Not a short term play, but decent long term prospects.
News 
Market Data 
Discover 
